Stock analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.
Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.
Check Out Our Latest Stock Analysis on Accelerate Diagnostics
Accelerate Diagnostics Stock Performance
Insider Activity at Accelerate Diagnostics
In related news, Director John Patience bought 200,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average price of $1.57 per share, with a total value of $314,000.00. Following the transaction, the director now owns 653,224 shares of the company’s stock, valued at $1,025,561.68. The trade was a 44.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 43.60% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent quarter. Institutional investors own 17.14% of the company’s stock.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Featured Stories
- Five stocks we like better than Accelerate Diagnostics
- The Significance of Brokerage Rankings in Stock Selection
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What is Put Option Volume?
- 3 Steel Stocks Soaring After Tariff Announcements
- Using the MarketBeat Stock Split Calculator
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.